semaglutide nash phase 3 A Placebo-Controlled Trial of Subcutaneous in Nonalcoholic Steatohepatitis ESSENCE - Semaglutide in Metabolic

[DOI] [PMC free article] [PubMed] [Google Scholar] 40.Mundt JC, Greist JH, Jefferson JW, et al

The SELECT trial (semaglutide, published 2023-2024) reported cardiovascular-event-reduction signals in research populations without prior metabolic-disease diagnosis

Bear in mind though that these drinks contain sugars, calories and electrolytes, which are all helpful in moderation, but can lead to an excessive intake of these components if consumed in large amounts

NAION is a very rare eye disease, and it's not an adverse drug reaction listed on the labels for semaglutide in the form of Ozempic, Rybelsus and Wegovy, Novo Nordisk said in a statement